Home LiteratureArticle Details
PMID: 15767435 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.

Journal of virology ·Vol. 79 ·No. 7 ·2005-04-00 ·Pages 4347-56

Platt EJ, Durnin JP, Kabat D

Abstract

Replication of human immunodeficiency virus type 1 (HIV-1) in diverse conditions limiting for viral entry into cells frequently leads to adaptive mutations in the V3 loop of the gp120 envelope glycoprotein. This has suggested that the V3 loop limits the efficiencies of HIV-1 infections, possibly by directly affecting gp120-coreceptor affinities. In contrast, V3 loop mutations that enable HIV-1(JR-CSF) to use the low-affinity mutant coreceptor CCR5(Y14N) are shown here to have negligible effects on the virus-coreceptor affinity but to dramatically accelerate the irreversible conformational conversion of the envelope gp41 subunits from a three-stranded coil into a six-helix bundle. This slow step is blocked irreversibly by the inhibitor T-20. To further evaluate the role of entry rates in controlling infection efficiencies and viral adaptations, we developed methods to quantitatively measure viral entry kinetics. The virions were adsorbed by spinoculation at 4 degrees C onto HeLa-CD4/CCR5 cell clones that either had limiting or saturating concentrations of CCR5. After warming to 37 degrees C, the completion of entry was monitored over time by the resistance of infections to the competitive CCR5 inhibitor TAK-779. Our results suggest that the efficiency of entry of cell-attached infectious HIV-1 is principally controlled by three kinetic processes. The first is a lag phase that is caused in part by the concentration-dependent reversible association of virus with CD4 and CCR5 to form an equilibrium assemblage of complexes. Second, this assembly step lowers but does not eliminate a large activation energy barrier for a rate-limiting, CCR5-dependent conformational change in gp41 that is sensitive to blockage by T-20. The rate of infection therefore depends on the fraction of infectious virions that are sufficiently saturated with CCR5 to undergo this conformational change and on the magnitude of the activation energy barrier. Although only a small fraction of fully assembled viral complexes overcome this barrier per hour, the ensuing steps of entry are rapidly completed within 5 to 10 min. Thus, this barrier limits the overall flow rate at which the attached virions enter cells, but it has no effect on the lag time that precedes this entry flow. Third, a relatively rapid and kinetically dominant process of viral inactivation, which may partly involve endocytosis, competes with infectious viral entry. Our results suggest that the V3 loop of gp120 has a major effect on the rate-limiting coreceptor-dependent conformational change in gp41 and that adaptive viral mutations, including V3 loop mutations, function kinetically by accelerating this inherently slow step in the entry pathway.

MeSH Terms
Amides/pharmacology Anti-HIV Agents/pharmacology CCR5 Receptor Antagonists CD4 Antigens/physiology Enfuvirtide HIV Envelope Protein gp120/genetics,physiology HIV Envelope Protein gp41/chemistry,pharmacology,physiology HIV Fusion Inhibitors/pharmacology HIV-1/drug effects,physiology HeLa Cells Humans Kinetics Peptide Fragments/genetics,pharmacology,physiology Protein Conformation/drug effects Quaternary Ammonium Compounds/pharmacology Receptors, CCR5/genetics,physiology Virus Replication/drug effects
Chemicals
Amides Anti-HIV Agents CCR5 Receptor Antagonists CD4 Antigens HIV Envelope Protein gp120 HIV Envelope Protein gp41 HIV Fusion Inhibitors HIV envelope protein gp120 (305-321) Peptide Fragments Quaternary Ammonium Compounds Receptors, CCR5 Enfuvirtide TAK 779
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Platt Emily J
Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, OR 97239-3098, USA.
Durnin James P
Kabat David
References (60)
60 references, click to expand
  1. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.
    Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10537-41 PMID: 1438243
  2. Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1
    J Clin Invest. 2000 Dec;106(12):1569 PMID: 11120764
  3. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock.
    Nat Immunol. 2000 Oct;1(4):285-9 PMID: 11017098
  4. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.
    Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12718-23 PMID: 11606733
  5. HIV entry and its inhibition.
    Cell. 1998 May 29;93(5):681-4 PMID: 9630213
  6. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.
    J Virol. 1998 Apr;72(4):2855-64 PMID: 9525605
  7. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans.
    J Virol. 1998 May;72(5):3623-34 PMID: 9557643
  8. Fluorescence resonance energy transfer-based HIV-1 virion fusion assay.
    Methods Mol Biol. 2004;263:333-44 PMID: 14976375
  9. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.
    Nature. 1996 Aug 22;382(6593):722-5 PMID: 8751444
  10. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.
    J Virol. 2000 Nov;74(21):10074-80 PMID: 11024136
  11. Polymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency viruses.
    J Virol. 1997 Nov;71(11):8642-56 PMID: 9343222
  12. Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.
    J Virol. 2005 Apr;79(7):4357-68 PMID: 15767436
  13. Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates resulting from the delta ccr5 mutation.
    J Virol. 1997 Apr;71(4):3219-27 PMID: 9060685
  14. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):763-7 PMID: 6096719
  15. Cell surface receptors, virus entry and tropism of primate lentiviruses.
    J Gen Virol. 2002 Aug;83(Pt 8):1809-29 PMID: 12124446
  16. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.
    J Virol. 2002 Sep;76(17):8953-7 PMID: 12163614
  17. Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.
    J Med Chem. 2003 Sep 25;46(20):4236-9 PMID: 13678401
  18. HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation.
    Mol Biol Cell. 2003 Mar;14(3):926-38 PMID: 12631714
  19. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
    J Virol. 2004 Mar;78(6):2790-807 PMID: 14990699
  20. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
    Nature. 1996 Nov 14;384(6605):179-83 PMID: 8906795
  21. Mechanisms of viral membrane fusion and its inhibition.
    Annu Rev Biochem. 2001;70:777-810 PMID: 11395423
  22. A biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptors.
    Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11215-20 PMID: 11005830
  23. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.
    J Virol. 1988 Jun;62(6):2026-32 PMID: 3130494
  24. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54 PMID: 12444251
  25. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity.
    J Virol. 1988 Oct;62(10):3779-88 PMID: 3047430
  26. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1.
    J Virol. 2000 Aug;74(15):7005-15 PMID: 10888639
  27. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.
    Proc Natl Acad Sci U S A. 2000 May 9;97(10):5639-44 PMID: 10779565
  28. Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites.
    J Virol. 2003 Feb;77(3):1666-71 PMID: 12525600
  29. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture.
    J Virol. 1991 Jan;65(1):356-63 PMID: 1985204
  30. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.
    Annu Rev Immunol. 1999;17:657-700 PMID: 10358771
  31. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop.
    J Virol. 1997 Sep;71(9):7136-9 PMID: 9261451
  32. Use of a new CD4-positive HeLa cell clone for direct quantitation of infectious human immunodeficiency virus from blood cells of AIDS patients.
    J Infect Dis. 1991 Jan;163(1):64-70 PMID: 1984477
  33. Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions.
    J Virol. 2001 Mar;75(6):2993-3000 PMID: 11222724
  34. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.
    Cell. 1999 Oct 1;99(1):103-15 PMID: 10520998
  35. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1.
    J Virol. 1997 Feb;71(2):873-82 PMID: 8995603
  36. Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis.
    J Virol. 2001 Nov;75(22):11166-77 PMID: 11602756
  37. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
    Proc Natl Acad Sci U S A. 1999 May 11;96(10):5698-703 PMID: 10318947
  38. Change in coreceptor use correlates with disease progression in HIV-1--infected individuals.
    J Exp Med. 1997 Feb 17;185(4):621-8 PMID: 9034141
  39. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
    Virology. 2004 Mar 30;321(1):8-22 PMID: 15033560
  40. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.
    Nature. 1996 Nov 14;384(6605):184-7 PMID: 8906796
  41. Virus-cell and cell-cell fusion.
    Annu Rev Cell Dev Biol. 1996;12:627-61 PMID: 8970739
  42. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.
    J Virol. 2001 Dec;75(24):12266-78 PMID: 11711617
  43. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):767-8 PMID: 6083454
  44. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.
    J Virol. 2004 Apr;78(7):3742-52 PMID: 15016894
  45. The dynamics of CD4+ T-cell depletion in HIV disease.
    Nature. 2001 Apr 19;410(6831):974-9 PMID: 11309627
  46. Critical role of enhanced CD4 affinity in laboratory adaptation of human immunodeficiency virus type 1.
    AIDS Res Hum Retroviruses. 2000 Jun 10;16(9):871-82 PMID: 10875613
  47. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.
    Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):11013-8 PMID: 12930892
  48. Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes.
    J Virol. 2004 Feb;78(3):1375-83 PMID: 14722292
  49. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes.
    Nat Biotechnol. 2002 Nov;20(11):1151-4 PMID: 12355096
  50. T cell dynamics in HIV-1 infection.
    Annu Rev Immunol. 2003;21:265-304 PMID: 12524385
  51. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1.
    J Virol. 1994 Apr;68(4):2570-7 PMID: 8139036
  52. Changes in both gp120 and gp41 can account for increased growth potential and expanded host range of human immunodeficiency virus type 1.
    J Virol. 1992 Jul;66(7):4445-51 PMID: 1602552
  53. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.
    Cell. 1996 Aug 9;86(3):367-77 PMID: 8756719
  54. Segregation of CD4 and CXCR4 into distinct lipid microdomains in T lymphocytes suggests a mechanism for membrane destabilization by human immunodeficiency virus.
    J Virol. 2002 Feb;76(4):1802-15 PMID: 11799176
  55. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.
    J Virol. 1992 Mar;66(3):1354-60 PMID: 1738194
  56. Endocytic entry of HIV-1.
    Curr Biol. 2000 Aug 24;10(16):1005-8 PMID: 10985390
  57. Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1.
    J Virol. 1998 Mar;72(3):2208-12 PMID: 9499078
  58. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection.
    Nat Med. 1996 Nov;2(11):1244-7 PMID: 8898753
  59. HIV-1 entry inhibitor entrances.
    Trends Pharmacol Sci. 2004 Mar;25(3):117-20 PMID: 15058280
  60. A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1.
    J Biol Chem. 1999 Jan 22;274(4):1905-13 PMID: 9890944
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2005-04-00
Pages
4347-56
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC1061535
Subset
IM
Grants
NCI NIH HHS · R01 CA067358 · United States
NCI NIH HHS · R56 CA067358 · United States
NCI NIH HHS · CA67358 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com